Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan
No Thumbnail Available
Authors
Nadeem, Iftikhar
Ul Munamm, Syed Ata
Ur Rasool, Masood
Fatimah, Mufakhara
Abu Bakar, Muhammad
Jordon
Rana, Zaid Khalid
Khatana, Usman Feroze
Jordan, Louise
Saqlain, Muhammad
Issue Date
2023-06
Type
Scientific Paper
Language
Keywords
Research Subject Categories::MEDICINE::Dermatology and venerology,clinical genetics, internal medicine::Internal medicine::Lung diseases , Research Subject Categories::INTERDISCIPLINARY RESEARCH AREAS::Older people and ageing
Alternative Title
Abstract
The first case of novel SARS-COV-2 (COVID-19) in Pakistan was detected on 26 February 2020. Pharmacological and non-pharmacological strategies have been tried to lessen the mortality and morbidity burden. Various vaccines have been approved. The Drug Regulatory Authority of Pakistan gave emergency approval for Sinopharm (BBIBP-CorV) COVID-19 vaccine in December 2021. The phase 3 trial of BBIBP-CorV included only 612 participants aged 60 years and above. The primary aim of this study was to assess the safety and efficacy of BBIBPP-CorV (Sinopharm) vaccine within the Pakistani adult population aged 60 or above. The study was carried out in the Faisalabad district of Pakistan.
Methods: A test negative case-control study design was used to assess safety and efficacy of BBIBP-CorV in individuals aged 60 and above against symptomatic infection, hospitalisations and mortality due to SARS-CoV-2 among vaccinated and unvaccinated individuals. ORs were calculated using logistic regression model at 95% CI. ORs were used to calculate the vaccine efficacy (VE) by using the following formula.VE= (1-OR) ×100.
Results: 3426 individuals with symptoms of COVID-19 were PCR tested between 5 May 2021 and 31 July 2021. The results showed that Sinopharm vaccine 14 days after the second dose was efficient in reducing the risk of symptomatic COVID-19 infection, hospitalisations and mortality by 94.3%, 60.5% and 98.6%, respectively, among vaccinated individuals with a significant p value of 0.001.
Conclusion: Our study showed that BBIBP-CorV vaccine is highly effective in preventing infection, hospitalisations and mortality due to COVID-19.
Description
Citation
Nadeem I, Ul Munamm SA, Ur Rasool M, Fatimah M, Abu Bakar M, Rana ZK, Khatana UF, Jordon L, Saqlain M, Mahdi N, McLoughlin H. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan. Postgrad Med J. 2023 Jun 8;99(1171):463-469. doi: 10.1136/postgradmedj-2022-141649. PMID: 37294716.
Publisher
License
Journal
Volume
Issue
PubMed ID
ISSN
https://academic.oup.com/pmj/article-abstract/99/1171/463/7192080?redirectedFrom=fulltext&login=false